Malignant Uterine Corpus Neoplasm — Trials

Malignant Uterine Corpus Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,571 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 411
Recruiting: 227
Ph III recruiting: 25
Growth YoY: +1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.6%
Trials / 1,000 deaths: 50.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 1,051–1,100 of 1,571 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01280045	Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy	terminated	N/A	5	University of Sao PauloOTHER	0	Aug 13, 2020	clinicaltrials
NCT01738724	Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin	terminated	Phase 4	14	University of Sao PauloOTHER	0	Aug 13, 2020	clinicaltrials